Key result
Reducing systolic blood pressure by 10-12 mmHg and diastolic by 5-6 mmHg substantially reduces cardiovascular risk, with ARBs like telmisartan emerging as logical choices for combination therapy.
Why the study?
Does aggressive blood pressure lowering with ARBs reduce cardiovascular risk in patients with hypertension?
Population
Patients with hypertension
Design
Review
Authors
Loading...
Supports intensive BP lowering below current targets; leaves open the precise J-curve threshold in treated patients.
Does aggressive blood pressure lowering with ARBs reduce cardiovascular risk in patients with hypertension?
Aggressive blood pressure control using combination therapy, particularly with ARBs, is crucial for reducing cardiovascular risk in hypertensive patients.
Gordon T. McInnes (2005) conducted a review in Hypertension and cardiovascular risk. Blood pressure lowering therapy (including ARBs such as telmisartan) was evaluated. Reducing systolic blood pressure by 10-12 mmHg and diastolic by 5-6 mmHg substantially reduces cardiovascular risk, with ARBs like telmisartan emerging as logical choices for combination therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: